Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | ACP3 | P15309 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL98965 | 0.90 | ALDH1A1 (0.48) | ALDH1A1HSD17B10KDM4ELMNAMEN1 | |
| SCHEMBL99836 | 0.82 | ALDH1A1 (0.46) | ALDH1A1HSD17B10KDM4EGAAMEN1 | |
| SCHEMBL30829144 | 0.81 | ADORA3 (0.40) | ACP3HSD17B10KDM4ECYP3A4MAPT | |
| SCHEMBL10091946 | 0.81 | ALDH1A1 (0.47) | ALDH1A1HSD17B10KDM4EGAALMNA | |
| SCHEMBL28023416 | 0.78 | ALDH1A1 (0.49) | ALDH1A1HSD17B10KDM4EGAALMNA | |
| SCHEMBL26127465 | 0.78 | KDM4E (0.37) | ALDH1A1KDM4EGAAMEN1MAPT | |
| SCHEMBL26124955 | 0.78 | S100A4 (0.36) | ALDH1A1KDM4EGAALMNAMEN1 | |
| SCHEMBL26124888 | 0.78 | MAOB (0.36) | ALDH1A1KDM4EGAAMEN1MAPT | |
| SCHEMBL1689403 | 0.77 | POLB (0.42) | ALDH1A1HSD17B10KDM4ELMNAMEN1 | |
| SCHEMBL29655180 | 0.77 | ALDH1A1 (0.47) | ALDH1A1HSD17B10KDM4EGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2824098-B1 | Method for the preparation of 4-[3-(4-cyclopropanecarbonyl- piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | KUDOS PHARM LTD (GB) | 2016-06-22 | — | — | EP | claimed |
| EP-2824098-A1 | Method for the preparation of 4-[3-(4-cyclopropanecarbonyl- piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | Kudos Pharmaceuticals Limited (GB) | 2015-01-14 | — | — | EP | claimed |
| US-7692006-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-04-06 | — | — | US | claimed |
| EP-2064189-A2 | POLYMORPHIC FORM OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | Kudos Pharmaceuticals Limited (GB) | 2009-06-03 | — | — | EP | claimed |
| US-20080146575-A1 | 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic with BRCA2 deficient phenotype; septic shock, ischemic injury, multiple sclerosis | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-06-19 | — | — | US | claimed |
| WO-2008047082-A2 | POLYMORPHIC FORM OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-04-24 | — | — | WO | claimed |
| US-12145925-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | ATLASMEDX, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| EP-4384501-A1 | PROCESS FOR THE PREPARATION OF OLAPARIB, AND CRYSTALLINE FORM THEREOF | Glenmark Life Sciences Limited (IN) | 2024-06-19 | — | — | EP | disclosed |
| US-20240174651-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-05-30 | — | — | US | disclosed |
| EP-4284372-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | University of Florida Research Foundation, Incorporated (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-3475272-B1 | PHTHALAZINE DERIVATIVES AS INHIBITORS OF PARP1, PARP2 AND/OR TUBULIN USEFUL FOR THE TREATMENT OF CANCER | UNIV CALIFORNIA (US) | 2023-09-13 | — | — | EP | disclosed |
| WO-2023017393-A1 | PROCESS FOR THE PREPARATION OF OLAPARIB, AND CRYSTALLINE FORM THEREOF | GLENMARK LIFE SCIENCES LIMITED (IN) | 2023-02-16 | — | — | WO | disclosed |
| US-RE49338-E1 | Phthalazinone derivatives and manufacturing process thereof | IDIENCE CO., LTD. (KR) | 2022-12-20 | — | — | US | disclosed |
| US-5238715-A | Aluminum oxide and/or aluminum hydroxide layer bonded to aluminum alloy body; organophosphorous ester bonded to the oxide/hydroxide layer; polymer layer bonded to phosphorous layer | ALUMINUM COMPANY OF AMERICA (US) | 1993-08-24 | — | — | US | disclosed |
| US-5132181-A | Protective coating on aluminum | ALUMINUM COMPANY OF AMERICA (US) | 1992-07-21 | — | — | US | disclosed |
| US-5126210-A | Chemically bonded organic protective coating on barrier oxide layer | ALUMINUM COMPANY OF AMERICA (US) | 1992-06-30 | — | — | US | disclosed |
| US-5124022-A | Hydration resistant composite layer formed on aluminum by anodizing in organic phosphorus containing electrolyte | ALUMINUM COMPANY OF AMERICA (US) | 1992-06-23 | — | — | US | disclosed |
| US-5103550-A | Coating aluminum base with aluminum oxide or hydroxide; treating with organic phosphorus-containing compound; applying polymer | ALUMINUM COMPANY OF AMERICA (US) | 1992-04-14 | — | — | US | disclosed |
| US-5059258-A | Protective coatings | ALUMINUM COMPANY OF AMERICA (US) | 1991-10-22 | — | — | US | disclosed |
| US-5032237-A | Anodizing, protective | ALUMINUM COMPANY OF AMERICA (US) | 1991-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146575-A1 | 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic with BRCA2 deficient phenotype; septic shock, ischemic injury, multiple sclerosis | PARP1, PARP11, PARP2 | ALDH1A1 1432/4885ACP3 3656/4885HSD17B10 1956/4885 |
| US-20240174651-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | NLN, OAT, PC | ALDH1A1 424/4885ACP3 919/4885HSD17B10 213/4885 |
| US-12145925-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | PARP2, PARP12, PARP1 | ALDH1A1 1089/4885ACP3 973/4885HSD17B10 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.